“We are getting close to a ‘tipping point’ in genomics and medicine where it will make economic sense to DNA sequence everyone. The reason for this is that there is mounting evidence of the value of this data in both rare and common diseases. As a genetic test only needs to be completed once, soon the benefits will outweigh the costs on a population / healthcare system level. This will spur even more innovation in the ‘application layer’ including the development of new genetically targeted medicines and in prediction and prevention of common diseases like type 2 diabetes, breast cancer, and cardiovascular disease."